Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07318324 · ClinicalTrials.gov registry record · Phase 1
Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT07318324: Recruiting Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT07318324 is a Phase 1 study that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 31 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07318324, a Phase 1 study, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
To find the recommended dose of the combination of avutometinib, defactinib, and everolimus in patients with endometrial cancer that is recurrent and has abnormal RAS activity. The safety and effects of this combination will also be studied.
Interventions
- DRUG Avutometinib
- DRUG Everolimus
- DRUG defactinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2026-05-13 |
| Est. Completion | 2030-08-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07318324
The ClinicalTrials.gov registry entry for NCT07318324 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Avutometinib is the first listed.
NCT07318324 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07318324 about?
NCT07318324 is a clinical study titled "Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer". To find the recommended dose of the combination of avutometinib, defactinib, and everolimus in patients with endometrial cancer that is recurrent and has abnormal RAS activity. The safety and effects of this combination will also be studied.
What is the current status of trial NCT07318324?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2026-05-13. Estimated completion is 2030-08-01.
What interventions are being tested in trial NCT07318324?
The interventions under investigation include: Avutometinib (DRUG), Everolimus (DRUG), defactinib (DRUG).
Who is sponsoring clinical trial NCT07318324?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.